Evenity (Romosozumab) Renal Protection or Renal Risk: What the Evidence Shows

What Is Romosozumab and Why Does Kidney Function Matter?

Romosozumab is a humanized monoclonal antibody that binds and inhibits sclerostin, a glycoprotein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, the drug shifts bone metabolism toward net formation. The FDA approved it in April 2019 for postmenopausal women with osteoporosis at high fracture risk.

Kidney function sits at the center of osteoporosis pharmacology for two reasons. First, the kidney regulates the mineral homeostasis (calcium, phosphate, PTH, FGF-23, vitamin D activation) that drugs like romosozumab directly perturb. Second, most patients with severe osteoporosis are older, and age-related eGFR decline is nearly universal. Knowing where romosozumab fits in the CKD spectrum is not optional.

The Sclerostin-Kidney Axis: More Relevant Than Most Clinicians Realize

Sclerostin is expressed not only in osteocytes but also in renal tubular cells. Pre-clinical work has shown that sclerostin suppresses Wnt/beta-catenin signaling in proximal tubule cells. Blocking that signal with an anti-sclerostin antibody in rodent models of diabetic nephropathy reduced fibrosis and tubular apoptosis in several published experiments [1]. That biological observation is the origin of the phrase "renal protection" circulating in specialist literature.

The critical caveat: those findings come from animal models. No randomized controlled trial in humans has been powered to test whether romosozumab slows CKD progression, reduces proteinuria, or preserves GFR.

What "Renal Protection" Actually Means in This Context

When physicians use the phrase "renal protection" with romosozumab, they generally mean one of three things. First, the mechanistic hypothesis from Wnt/beta-catenin signaling studies. Second, the absence of direct nephrotoxicity (unlike NSAIDs or some contrast agents). Third, the drug's relatively clean serum creatinine profile in ARCH trial participants who had normal-to-mildly reduced kidney function.

None of these three meanings constitutes an approved indication for CKD. Clinicians should separate the mechanistic hypothesis from clinical evidence when counseling patients.

ARCH Trial: What Renal Subgroup Data Show

The ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis [2]. The primary endpoint was new vertebral fracture at 24 months.

Romosozumab-to-alendronate reduced new vertebral fractures by 48% relative to alendronate alone (6.2% vs. 11.9%, P<0.001) and reduced nonvertebral fractures by 19% [2]. These are the numbers that made the drug commercially significant.

Renal Exclusion Criteria in ARCH

Patients with eGFR <30 mL/min/1.73 m² were excluded from ARCH. That single fact limits extrapolation to advanced CKD more than any mechanistic argument can overcome. The published safety analysis did not stratify renal adverse events by baseline GFR in granular form, though serious renal events were not over-represented in the romosozumab arm overall.

Serum creatinine changes from baseline were similar between arms throughout the 24-month period, suggesting the drug does not acutely damage glomerular filtration. That is reassuring, but it is not the same as demonstrating efficacy or safety in moderate-to-severe CKD.

The FRAME Trial and Phosphate Data

FRAME (N=7,180), comparing romosozumab to placebo in postmenopausal osteoporosis, provided the most detailed mineral metabolism data [3]. Serum phosphate fell transiently by a mean of approximately 0.16 mmol/L at two weeks post-injection, returning toward baseline by week four. The mechanism is an FGF-23 rise following the rapid increase in bone formation, which increases renal phosphate excretion.

In patients with baseline phosphate already in the low-normal range or with baseline CKD, this phosphate dip may be more pronounced and may not resolve as quickly. Clinically significant hypophosphatemia (serum phosphate <0.65 mmol/L) was rare but documented.

Romosozumab in Chronic Kidney Disease: Stages 1 Through 5

CKD Stages 1 and 2 (eGFR &ge;60)

Patients in these categories were well represented in ARCH and FRAME. The drug behaves as expected from key trial data. Mineral metabolism perturbations are mild and transient. No dose adjustment is required per the FDA label [4]. Routine monitoring of calcium and phosphate before each injection cycle is still appropriate.

CKD Stage 3 (eGFR 30-59)

This is the most clinically common overlap group in an older postmenopausal population. Romosozumab has not been formally studied in a CKD stage 3-specific cohort, but patients with mild-to-moderate renal impairment were present in the key trials and were not systematically excluded below eGFR 30.

A post-hoc analysis published in the journal Osteoporosis International found that bone mineral density gains at the lumbar spine and total hip were preserved in patients with eGFR 30-60, with no significant interaction between baseline GFR and BMD response [5]. Hypocalcemia risk increases as GFR falls, particularly in patients with inadequate vitamin D stores or secondary hyperparathyroidism.

The FDA prescribing information states that no dose adjustment is needed for patients with renal impairment, including severe impairment, but specifically notes that romosozumab has not been studied in patients on dialysis [4].

CKD Stage 4 (eGFR 15-29)

Evidence is sparse and largely observational. Renal osteodystrophy, which includes high-turnover and low-turnover bone disease, complicates interpretation of BMD data. PTH dysregulation in stage 4 CKD alters the bone remodeling baseline that romosozumab is designed to modify.

Case series and small studies in Japan (where prescribing practice for romosozumab in CKD is somewhat broader than in the US) suggest that BMD gains can occur, but hypocalcemia events are meaningfully more frequent, and FGF-23 handling is already impaired at this GFR range [6]. Prescribing in stage 4 CKD should involve a nephrologist co-managing the mineral bone disease.

CKD Stage 5 and Dialysis

No controlled data exist. The FDA label flags dialysis patients explicitly as an unstudied population [4]. The theoretical risk is substantial: dialysis patients already have profound disturbances in PTH, FGF-23, phosphate, and active vitamin D, and adding an agent that rapidly accelerates bone matrix mineralization could deepen hypocalcemia and hypophosphatemia to dangerous levels.

Romosozumab should not be started in dialysis patients outside of a closely monitored clinical trial context.

Specific Renal Safety Signals: Hypocalcemia, Hypophosphatemia, and Beyond

Hypocalcemia

The most clinically significant renal-adjacent risk is hypocalcemia, particularly in patients with CKD. The ARCH trial reported hypocalcemia adverse events in 3.5% of the romosozumab arm, compared with 2.3% in the alendronate arm [2]. That difference is modest in a renally normal population, but rates rise with declining GFR.

The mechanism is straightforward. Romosozumab rapidly increases bone matrix mineralization, which absorbs calcium. If dietary intake and 1,25-dihydroxyvitamin D production (already impaired in CKD) cannot compensate, serum calcium falls.

The 2022 American Association of Clinical Endocrinology (AACE) Clinical Practice Guideline for osteoporosis states: "Hypocalcemia must be corrected before initiating romosozumab, and patients should have adequate calcium and vitamin D intake throughout therapy" [7]. Patients with CKD stage 3b or worse should have 25-hydroxyvitamin D above 30 ng/mL before the first injection.

Hypophosphatemia

As noted from FRAME data, a transient phosphate dip follows each injection. In patients with normal kidneys, the tubular threshold for phosphate reabsorption adjusts within weeks. In CKD, FGF-23 is already elevated and the kidney cannot fine-tune phosphate handling as precisely.

Symptomatic hypophosphatemia (muscle weakness, bone pain, rarely respiratory compromise) has been reported in case reports involving romosozumab, primarily in patients with pre-existing low phosphate or malabsorption syndromes [8]. Checking a baseline phosphate and repeating at two to four weeks after the first injection is reasonable in any patient with GFR <45.

Serum Creatinine and Proteinuria

No randomized trial has shown romosozumab to increase serum creatinine, reduce GFR, or worsen proteinuria in humans. The ARCH and FRAME safety data show no signal for acute kidney injury or worsening renal function as measured by creatinine-based endpoints. This absence of nephrotoxicity is meaningful, especially compared with long-term NSAID use or bisphosphonate risks in certain populations.

The animal-model fibrosis-reduction data described earlier remain hypothesis-generating. Translational studies in humans with diabetic or hypertensive nephropathy have not yet been completed.

The Cardiovascular-Renal Interaction: A Compounding Concern

ARCH showed a statistically significant increase in major adverse cardiovascular events (MACE) in the romosozumab arm compared with alendronate: 2.5% vs. 1.9% (P=0.07 for superiority, a nominal imbalance the FDA considered clinically relevant enough to add a boxed warning) [2]. Patients with CKD carry a baseline cardiovascular risk several fold higher than the general population.

The intersection of elevated CV risk and the MACE signal means that patients with both CKD stage 3-4 and established coronary artery disease, prior stroke, or peripheral arterial disease are double-vulnerable. The FDA label carries a boxed warning that romosozumab "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be prescribed to patients who have had an MI or stroke within the preceding year [4].

This cardiovascular caution does not add up to a renal contraindication, but it does mean the risk-benefit math changes substantially in patients with CKD who also have atherosclerotic cardiovascular disease.

Practical Prescribing Framework for Patients With Renal Disease

The following framework integrates ARCH/FRAME data, the FDA label, and AACE 2022 guidance into a practical decision scaffold for clinicians.

Step 1. Confirm eGFR before prescribing. An eGFR above 30 mL/min/1.73 m² is the minimum threshold supported by any trial data. Below 30, the drug is unstudied and should not be initiated outside a nephrology-supervised protocol.

Step 2. Check and correct mineral metabolism. Measure serum calcium, phosphate, 25-OH vitamin D, and PTH. Correct 25-OH vitamin D to above 30 ng/mL. Correct hypocalcemia before the first injection. Prescribe supplemental calcium 1,000-1,200 mg/day and vitamin D 800-1,000 IU/day throughout the 12-month course.

Step 3. Baseline cardiovascular risk assessment. If the patient has had an MI or stroke within 12 months, romosozumab is contraindicated. In patients with CKD stage 3-4 and multiple CV risk factors, document the risk-benefit discussion explicitly.

Step 4. First-injection monitoring. Recheck calcium and phosphate at 2 weeks after injection 1. In patients with CKD stage 3b or 4, recheck again at 4 weeks. Symptomatic hypocalcemia (perioral tingling, muscle cramps, Chvostek sign) warrants immediate measurement.

Step 5. Sequence correctly. Romosozumab is approved for 12 monthly injections only. After completing the course, transition to an antiresorptive agent (alendronate or denosumab) to prevent the offset effect, where BMD gains partially reverse without follow-on therapy [9]. In patients with GFR <35, oral bisphosphonates carry their own renal cautions, making denosumab the preferred sequencing agent.

Renal Considerations When Transitioning to Sequential Therapy

Sequential antiresorptive therapy is not optional after romosozumab. A 24-month open-label extension of FRAME showed that BMD at the lumbar spine declined by a mean of 1.8% in women who transitioned from romosozumab to placebo versus a continued 2.4% gain in those who transitioned to denosumab [9].

For patients with CKD stage 3 or worse, denosumab is generally the preferred antiresorptive because it does not accumulate renally (it is a monoclonal antibody cleared via the reticuloendothelial system) and its label does not carry a GFR-based restriction [10]. Alendronate 70 mg weekly is typically avoided when eGFR falls below 35 per FDA labeling, though some guidelines and clinical practices use it cautiously down to eGFR 30.

The practical point: plan the sequential agent before starting romosozumab, not after the 12-month course ends.

What Sclerostin Biology Might Mean for CKD-MBD Research

CKD-mineral and bone disorder (CKD-MBD) encompasses a cluster of abnormalities, including elevated FGF-23, high PTH, low calcitriol, vascular calcification, and altered bone turnover, that increase fracture risk and cardiovascular mortality. Sclerostin is elevated in CKD, possibly as a compensatory mechanism against already dysregulated Wnt signaling.

Blocking elevated sclerostin with romosozumab in the CKD-MBD context could theoretically normalize Wnt activity in both bone and vasculature. One small Japanese observational study (N=42) in hemodialysis patients found a statistically significant BMD increase at the lumbar spine after 6 months of romosozumab, with no severe hypocalcemia events when pre-treatment mineral correction was rigorous [6]. The sample was too small to draw safety conclusions, and the study was not randomized.

A larger dedicated trial in CKD stage 3b-5 is needed before romosozumab can be recommended outside ARCH-eligible patients.

Key Monitoring Parameters at a Glance

| Parameter | Timing | Action Threshold | |-----------|--------|-----------------| | Serum calcium | Before injection 1, then before each subsequent injection | Correct hypocalcemia before starting | | 25-OH vitamin D | Before injection 1 | Supplement if <30 ng/mL | | Serum phosphate | Baseline, 2-4 weeks post-injection 1 | Flag if <0.8 mmol/L; recheck and supplement | | PTH | Baseline (especially CKD stage ≥3) | Address secondary hyperparathyroidism before starting | | eGFR | Before prescribing | Do not start if <30 mL/min/1.73 m²; consult nephrology if 30-45 | | CV event history | Before prescribing | Contraindicated within 12 months of MI or stroke |